VERTEX PHARMACEUTICAL CEDEAR EACH 101 REPR 1 ORDVERTEX PHARMACEUTICAL CEDEAR EACH 101 REPR 1 ORDVERTEX PHARMACEUTICAL CEDEAR EACH 101 REPR 1 ORD

VERTEX PHARMACEUTICAL CEDEAR EACH 101 REPR 1 ORD

No trades
See on Supercharts

VRTX fundamentals

VERTEX PHARMACEUTICAL CEDEAR EACH 101 REPR 1 ORD financial statements, including revenue, expenses, and profit

The total revenue of VRTX for the last quarter is 2.95 T ARS, and it's 1.02% lower compared to the previous quarter. The net income of Q1 25 is 693.45 B ARS.

Q2 '17
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: ARS
Q2 '17
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
TTM
Total revenueYoY growth
Gross profitYoY growth
Pretax incomeYoY growth
Net incomeYoY growth
EBITDAYoY growth
EBITYoY growth